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Abstract. The threat of nuclear terrorism by the deliberate detonation of a nuclear weapon or
radiological dispersion device (“dirty bomb”) has made emergency response planning a priority. The only
FDA-approved treatments for contamination with isotopes of the transuranic elements Am, Pu, and Cm
are the Ca and Zn salts of diethylenetriaminepentaacetic acid (DTPA). These injectable products are not
well suited for use in a mass contamination scenario as they require skilled professionals for their
administration and are rapidly cleared from the circulation. To overcome the mismatch in the
pharmacokinetics of the DTPA and the biokinetics of these transuranic elements, which are slowly
released from contamination sites, the penta-ethyl ester of DTPA (C2E5) was prepared and formulated
in a nonaqueous gel for transdermal administration. When gels comprised of 40% C2E5, 40–45%
Miglyol® 840, and 15–20% ethyl cellulose were spiked with [14C]-C2E5 and applied to rat skin; over 60%
of the applied dose was absorbed within a 24-h period. Radioactivity was observed in urinary and fecal
excretions for over 3 days after removal of the gel. Using an 241Am wound contamination model,
transdermal C2E5 gels were able to enhance total body elimination and reduce the liver and skeletal
burden of 241Am in a dose-dependent manner. The efficacy achieved by a single 1,000 mg/kg dose to
contaminated rats was statistically comparable to intravenous Ca-DTPA at 14 mg/kg. The effectiveness of
this treatment, favorable sustained release profile of pro-chelators, and ease of administration support its
use following radiological emergencies and for its inclusion in the Strategic National Stockpile.
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INTRODUCTION
The increasing threat of nuclear terrorism as well as
incidents that involved the release of radioactive materials into
the environment, such as the accident at the Fukushima Daiichi
power plant in March 2011, has heightened the awareness for
many nations for the need to be prepared for such cataclysmic
events (1). Detonation of a nuclear weapon or a radiological
dispersion device (“dirty bomb”) near densely populated areas
could result in a large number of individuals being contaminated
by radionuclides via inhalation, ingestion, or through wounds.
Internalization of radioactive materials may result in acute
radiation sickness or chronic injuries including an increased risk
of developing cancers (2–5). Due to their abundance and
availability, isotopes of the transuranic elements americium
(Am), curium (Cm), and plutonium (Pu) are among the
radionuclides of greatest concern with respect to accidental or
deliberate contamination. The injuries and risks associated with
contamination by these radionuclides can be mitigated by the
intravenous (i.v.) administration of radionuclide decorporation
agents such as the calcium (Ca) and zinc (Zn) trisodium salts of
diethylenetriaminepentaacetic acid (DTPA). Ca–DTPA and
Zn–DTPA exert their pharmacological effect by sequestering
these radionuclides with high affinity and promoting the
elimination of the resulting chelate complexes from contami-
nated individuals. DTPA is administered via slow i.v. push, i.v.
infusion, or inhalation with a nebulizer (6); treatment is most
effective when administered shortly after contamination before
the transuranic radionuclides become fixed in tissues such as
liver and bone (7). The efficacy of Ca/Zn–DTPA injections has
been demonstrated for decades in workers injured in accidents
in the nuclear power industry (3,8–10).
Mass contamination scenarios call for effective and prompt
medical countermeasures for the affected populations. Current
DTPA treatment options do not meet the challenge imposed by a
mass casualty setting, in that skilled medical professionals who
may not be available are required to administer Ca/Zn–DTPA by
i.v. injection.Moreover,multiple injectionsmay be required due to
the short circulating half-life of DTPA. Stevens and colleagues
studied the clearance of DTPA in man and observed that
intravenously administered 14C-labeled DTPAwas quantitatively
excreted intact in urine in 24 h (11). The total body clearance of
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14C-labeledDTPA in rats 24 h after i.v. injection has been reported
to range from 94 to 100% with half-lives from 0.28 to
0.53 h and with no metabolic degradation (12,13). In
contrast, the release rates of internalized Am, Pu, and Cm
contaminants from wound sites to the systemic circulation
in various animal species range from 0.052 to 6.3% of the
administered radionuclides per day, a relatively slow and
steady transfer process (14).
It has been suggested that a chelating agent must be
maintained at a concentration of at least 10 to 25 μM in both
extracellular and intercellular fluids for a sustained duration to
ensure an optimal chelation effect of transuranic radionuclides
(15). In comparing the short half-life and rapid clearance of
DTPA after i.v. administration to the slow and sustained
introduction of radioactinides into the systemic circulation (14),
there is a mismatch between the pharmacokinetic profile of
intravenously administered DTPA and the biokinetic profile of
transuranic radionuclides. This mismatch leads to a period where
DTPA plasma concentrations are below the effective concentra-
tion required to chelate radionuclides in the systemic circulation
and, thus, may limit the effectiveness of the current parenteral
DTPA treatments. Previous efforts have addressed this mismatch
and produced encouraging results. Guilmette and Muggenburg
implanted subcutaneous osmotic pumps to continuously deliver
Zn–DTPA to dogs that had been contaminated with 241AmO2 by
inhalation, and achieved enhanced decorporation of 241Am (16).
DTPA has been entrapped in various liposome formulations for
prolonged circulation after i.v. administration, and improved
decorporation of 238Pu was achieved (13,17). However, these
approaches involve parenteral administration, thus making them
unsuitable for mass casualty scenarios after a major nuclear/
radiological emergency. As a result, a nonparenteral delivery
system which can provide sustained levels of chelators in the
circulation that match the biokinetic profile of actinides after
inhalation or wound contamination is highly desirable.
There are several efforts underway to improve the oral
bioavailability of Ca/Zn DTPA and other actinide decorporation
agents (18). DTPA is a synthetic polyamino carboxylic acid with
eight coordinate bond forming sites for complexingmetal ions.Due
to the presence of five carboxylic acid groups and three nitrogen
atoms, DTPA is highly ionic. Thus, Ca–DTPA and Zn–DTPA are
hydrophilic and are considered Class III compounds (high
solubility, low permeability) according to the Biopharmaceutical
Classification System. While oral formulations may provide for
sustained blood concentrations of DTPA, a zero-order release
profile can be achieved via transdermal drug delivery. Because
DTPA is hydrophilic (log Poct/water=−4.90) with a high melting
point (219–220°C), it is not a good candidate for transdermal
delivery (19,20). However, esterification of the five carboxylic
groups on DTPA produces lipophilic compounds which possess
desirable physicochemical properties for transdermal delivery
(21,22). We have prepared the penta-ethyl ester of DTPA,
designated as C2E5, and successfully incorporated it into a
nonaqueous gel formulation comprised of ethyl cellulose (EC)
and Miglyol® 840 with acceptable stability and rheological
properties (23). The selected 40% C2E5 nonaqueous gel was
applied to Sprague–Dawley (SD) rats at a dose of 200mg/kg C2E5
and achieved sustained release of C2E5 metabolites in vivo for an
extended duration (23).
The aim of the current studies was to assess the
transdermal absorption and excretion of C2E5 nonaqueous
gels and evaluate the radionuclide decorporation efficacy of
transdermal C2E5 nonaqueous gels at different dose levels
when applied 24 h after contamination using an 241Am wound
contamination model. To our knowledge, this is the first
report of the use of a transdermal formulation for the
systemic delivery of a radionuclide decorporation agent with
the goal of providing a sustained release pharmacokinetic




Miglyol 840 was purchased from Sasol (Hamburg,
Germany). EC (Ethocel Std 10 FP Premium polymer) with
an ethoxyl content of 48.0–49.5% was a gift from Dow
Chemical (Midland, MI, USA). C2E5 was prepared using the
Fischer esterification method by reacting DTPA with ethanol
under reflux in the presence of a hydrochloric acid catalyst
(22). [14C]-diethylenetriaminepentaacetic acid penta-ethyl
ester ([14C]-C2E5; 50 mCi/mmol) labeled at carbon-1
(carbonyl carbon) was purchased from American
Radiolabeled Chemicals, Inc. (St. Louis, MO). [241Am]-
americium nitrate solution for intramuscular (i.m.)
contamination of adult female SD rats was prepared from
[241Am]-americium chloride (Eckert & Ziegler Isotope
Products, Valencia, CA) by dilution with a solution of
concentrated nitric acid. Anhydrous ethanol, isopropyl
alcohol, and 30% hydrogen peroxide solution were
purchased from VWR International (Radnor, PA) and/or
Fisher Scientific (Fairlawn, NJ). Liquid scintillation cocktails
Ultima GoldTM and an aqueous-based tissue solubilizer
SolvableTM were purchased from PerkinElmer Life and
Analytical Sciences (Waltham, MA).
Preparation of C2E5 Nonaqueous Gel
C2E5 nonaqueous gels comprised of 40% C2E5, 15–20%
EC, and 40–45% Miglyol 840 were prepared using the solvent
evaporation method described previously (23). Briefly, pre-
dried EC particles were first dissolved in anhydrous ethanol
(10% w/v of EC in ethanol) to form a clear solution. This was
followed by addition of Miglyol 840 and C2E5 to form a
homogenous solution under stirring and subsequently remov-
ing ethanol under vacuum to yield the C2E5 nonaqueous gel.
[14C]-labeled C2E5 nonaqueous gel was prepared by adding
[14C]-C2E5 (50 mCi/mmol) into the C2E5 nonaqueous gels
followed by mixing. The [14C] content of the nonaqueous gel
was quantified by adding a fixed quantity of the gel with 10mL of
Ultima Gold™ scintillation cocktail and counting directly for
radioactivity by liquid scintillation counting (LSC) using a
Packard TriCarb 3100TR (PerkinElmer Life and Analytical
Sciences), with automatic quench correction. Samples were
counted for 10 min or until a 5% confidence level was achieved.
The specific activity of [14C]-labeled C2E5 nonaqueous gel was
calculated by dividing sample radioactivity by total sample mass.
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In Vivo Studies
Animals
All animal studies were conducted according to a
protocol approved by the University of North Carolina at
Chapel Hill Institutional Animal Care and Use Committee.
Ten-week-old adult female SD rats weighing from 200 to
300 g were used in these studies (Charles River Labs,
Raleigh, NC). Food and water were given ad libitum. The
animal room was kept at a controlled temperature on a 12/
12 h light/dark cycle (light exposure from 7 a.m. to 7 p.m.).
For the duration of the study, the rats were housed in
metabolic cages individually with daily urine and feces
collection until euthanasia on day 6 for mass balance study
and on day 7 for radionuclide decorporation study.
Absorption and Mass Balance Study with [14C]-Labeled C2E5
Nonaqueous Gels
To evaluate the absorption and mass balance of trans-
dermal delivery of the C2E5 nonaqueous gel, the [14C]-
labeled C2E5 nonaqueous gel was applied to rats at a 200 mg/
kg C2E5 dose level. Six adult female SD rats were
anesthetized with 2–3% isoflurane before the dorsal skin
between the cervical vertebrae, and anterior thoracic
vertebrae was clipped with caution to avoid irritation of the
skin that could increase absorption properties. The [14C]-
labeled gel was applied to a 2 cm×3 cm region using a cotton
swap. The mass of the gel applied was recorded for each rat
to permit actual dose determination, and a jacket with a
dermal insert (VWR International, Radnor, PA) was placed
on the rats to protect the area on which the gel was applied.
Twenty-four hours after application, the remaining gel at the
application site and the jacket with the dermal inserts were
carefully removed, and the recovered C2E5 content was
assayed by LSC. The animals were housed in metabolic cages
individually and were euthanized 6 days after application of
the gel. The animals were observed once daily and their body
weights recorded at pre-dose and prior to necropsy. Urine
and feces were collected daily until euthanasia on day 6, when
the liver and the skin from the application site and
surrounding area were also collected. Cage washes were
collected at the end of each experiment.
Collected urine samples were added to Ultima Gold™
scintillation cocktail at a ratio of 100 μL:10 mL and assayed
directly for radioactivity by LSC. For feces samples, the fecal
pellets were mixed and vortexed with 20 mL of a mixture of
acetonitrile and water (1:1 ratio) for 10 min, followed by a
30 min sonication, and subsequently centrifugation at 1,000×g at
4°C for 10min. The supernatant was transferred to a scintillation
vial for analysis by LSC (100 μL of feces extraction supernatant
sample directly dispersed into 10 mL of scintillation cocktail).
The extraction process was repeated until the sample count was
less than 1,000 disintegrations per minute per 100 μL of feces
extraction supernatant sample. The liquid cage wash samples
were processed in a manner similar to the urine samples and
assayed by LSC; the solid cage wastes were processed as fecal
pellets and assayed by LSC. For skin and liver samples, tissues
were mixed with tissue solubilizer (10% w/v of tissue to
solvable) and incubated at 50°C until the tissues became totally
solubilized. One milliliter of the solubilized tissue solution was
transferred to a vial, decolorized by incubation with 0.1 mL of
30%hydrogen peroxide solution for 1 h at 50°C, and then added
to 10 mL of scintillation cocktail for LSC analysis.
Radionuclide Decorporation of Contaminated Rats
To evaluate the efficacy of transdermal delivery of C2E5 in
a nonaqueous gel, a radionuclide decorporation efficacy study
was conducted in rats contaminated with 241Am. Adult female
SD rats were anesthetized with 2–3% isoflurane. All animals
were contaminated with [241Am]-americium nitrate solution
(250 mCi, 0.1 mL) via an i.m. injection in the anterior thigh
muscle. Dorsal skin between the cervical vertebrae and anterior
thoracic vertebrae was clipped with caution before application
of the gel. C2E5 doses of 200, 600, and 1,000mg/kg were applied
24 h post 241Am contamination to a 6 cm2 (2 cm×3 cm) area of
the clipped dorsal region using cotton swab. Fick's law (Eq. 1)





* A * Cveh ð1Þ
Where Jss=steady-state flux (in milligrams per hour), D=drug
diffusivity (in square centimeters per hour), h=membrane
thickness (in centimeters), Kp=drug's membrane-vehicle parti-
tion coefficient, Cveh=initial drug concentration (inmilligrams per
cubic centimeter) in the vehicle, and A=surface area (in square
centimeters). Keeping all other parameters constant, the flux of
the drug (Jss) is proportional to the surface area of drug
application on the skin. To assess the effect of application area,
the C2E5 nonaqueous gel was applied at a dose of 600 mg/kg
dose 24 h post 241Am contamination using cotton swab to an
18 cm2 (3 cm×6 cm) area of the clipped dorsal region. A jacket
with plastic dorsal insert was placed on the rats to protect the gel
application region. The mass of C2E5 gel applied was recorded
for each animal to permit the actual dose determination. Twenty-
four hours after application of the C2E5 gel, the remaining gel at
the application site and the jacket with the dermal insert were
carefully removed. The animals were housed in metabolic cages
individually and were euthanized 7 days after contamination.
Positive and negative controls included animals administered
with Ca–DTPA intravenously at a dose of 14 mg/kg 24 h after
contamination and animals untreated with any decorporation
agent. Daily observations and bodyweights were recorded at pre-
dose and prior to necropsy. Urine and feces were collected daily
until euthanasia, then the liver, kidneys, both femurs, the muscle
tissue around both femurs, and the pelt around the 241Am
injection site were also collected. Cage washes were collected at
the end of each experiment. As ∼35% of the decay of 241Am is
associated with photon emissions of 59.7 keV, 241Am present in
samples was quantified using a gamma counter (2470 Wizard 2,
Perkin Elmer). The samples were counted for 1 min using a 40–
80 keV energy detection window and were background-
corrected. Additionally, 241Am activity was quantified in 2×
0.1 mL aliquots of the dosing solution. For all samples, 241Am
content was expressed as a percentage of the injected dose. An
estimate of the total skeletal burden was made using the method
of Volf that was determined by the 241Am burden in the
contralateral femur multiplied by 20 (24). The 241Am retained
at the wound site was quantified by measuring the 241Am content
of the muscle surrounding the injection site plus the 241Am
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content in the femur. An estimate of muscle burden was
calculated based on the assumption that it represents 45% of
the body weight (24). The 241Am content of the muscle from the
opposite hind leg and animal body weight at sacrifice were used
to determine the estimated 241Am burden in the muscle. Total
recovery=total decorporation+liver 241Am content+kidney
241Am content+(skeleton 241Am content − 241Am in
contralateral femur)+241Am content at the wound site+muscle
241Am content+241Am content at the pelt around the 241Am
injection site.
Statistical Analysis
All data reported are mean ± standard deviation from a
given number of observations. Statistical analysis was performed
on the data from the efficacy study. To assess the treatment and
dose-induced changes in endpoint 241Amdata, i.e., liver, skeleton,
and wound site burden as well as total decorporation, one-way
ANOVA with Tukey's posttest was performed among three
C2E5 transdermal treatment groups at 200, 600, and 1,000 mg/kg
doses applied to a 6 cm2 application site, an untreated negative
control group, and a positive control group that received i.v. Ca–
DTPA. A second one-way ANOVA with Tukey's posttest was
performed among all the four C2E5 gel treatment groups,
negative untreated, and positive i.v. DTPA treatment groups.
To assess the sustained efficacy of transdermal C2E5 treatment,
daily 241Am decorporation in the urine and feces was analyzed by
repeated measures one-way ANOVAwith Dunnett's posttest to
compare each C2E5 treatment group with the untreated control
group. For all statistical analysis, p<0.05 was considered
significant. Statistical analyses were performed using the SAS
analysis system (v. 9.3; SAS Institute, Inc., Cary, NC).
RESULTS
Preparation of C2E5 Nonaqueous Gels
The structures of C2E5, its potential metabolites, includ-
ing DTPA tetra-ethyl ester (C2E4), DTPA triethyl ester
(C2E3), DTPA diethyl ester (C2E2), DTPA monoethyl ester
(C2E1), and the fully de-esterified metabolite (DTPA) are
depicted in Fig. 1. C2E5 is a clear, light yellow, slightly viscous
Newtonian liquid with a viscosity of ∼175 cP (22).
C2E5 nonaqueous gels comprised of 40% C2E5, 15–20%
EC, and 40–45% Miglyol 840 were prepared using the solvent
evaporation method described previously (23). The C2E5
gels were slightly yellow translucent semisolids with a density
of 1.02 g/cm3. C2E5 nonaqueous gels comprised of 40%
C2E5, 15–20% EC, and 40–45% Miglyol 840 were
radiolabeled with [14C]-C2E5 (specific activity=0.10 μCi/mg)
for a mass balance study. All gels were stored at 4°C until
applied to experimental animals.
Absorption and Mass Balance of [14C]-Labeled C2E5
Nonaqueous Gels
Significant C2E5 transdermal absorption was achieved after
topical application of the gels; approximately 32%of the 200mg/kg
C2E5 applied dose was recovered from the skin as unabsorbed
dose 24 h after application (Table I). Six days after application, a
[14C]-C2E5 mass balance of over 90% was obtained, with just
under 90% of the absorbed dose recovered in the excreta and
tissues (Table I). Low retention of C2E5 and its metabolites was
observed at the application site; only 1.6% of the applied dose was
present in the skin taken from the application site 6 days after
application (Table I). There was no significant [14C] radioactivity
remaining in the liver 6 days after application of the radiolabeled
gel, suggesting that C2E5 and its metabolites had relatively short
half-lives in plasma.
As demonstrated in Fig. 2, the urinary elimination of
[14C] radioactivity peaked 1 to 2 days after application and
gradually declined to the baseline level by the sixth day; the
fecal elimination of [14C] radioactivity peaked 2 days after
administration and gradually declined after the third day,
until it reached background levels by the sixth day.
In Vivo Radionuclide Decorporation
When C2E5 was applied transdermally 24 h after the
animals were contaminated with 241Am using the wound
contamination model (i.m. injection), the total 241Am
decorporation over a 7-day period was significantly enhanced
when compared with untreated control animals (Table II). The
enhanced decorporation showed a dose-dependent trend, with a
nonsignificant increase in decorporation between 0 and 200 mg/
kg dose, followed by significant increases in decorporation
between the 200 mg/kg dose and the 600 mg/kg dose (p<0.05)
and between the 600 mg/kg dose and the 1,000 mg/kg dose (p<
0.001). The 1,000 mg/kg C2E2 dose achieved decorporation that
was comparable to the current standard of care, i.v. DTPA. No
statistically significant differences were found in the 241Am
contents recovered from the wound sites among all the
experimental groups.
The observed increase in 241Am decorporation was in
part due to significant reductions in the 241Am burden in the
tissues of greatest concern, the liver, and skeleton. C2E5
significantly reduced liver burden compared with untreated
animals at all the doses tested. A dose-dependent effect of
C2E5 treatment was observed, with a decrease in mean liver
241Am burden as the applied C2E5 dose increased; this effect
was statistically significant when the 1,000 mg/kg dose was
compared with the 200 and the 600 mg/kg doses (p<0.001 and
p<0.05, respectively). The same trend was observed for the
mean skeletal burden, with a significant reduction compared
with untreated control animals at the 1,000 mg/kg dose. In all
tissues examined, the effect of the highest transdermal C2E5
dose on 241Am reduction was comparable with i.v. DTPA
(Table II). The daily excretion of 241Am in the urine (Fig. 3a)
and feces (Fig. 3b) of untreated animals and animals treated
with different doses of C2E5 further illustrated dose-
dependent efficacy. Additionally, although the residual gel
was removed from the skin 24 h after application (the same
time that the day 2 urine and feces samples were collected),
significantly enhanced decorporation was detected in the
urine and feces at least 3 days after the gel was removed.
As transdermal drug flux is dependent on the drug applica-
tion area, the decorporation efficacy of a C2E5 dose of 33.3mg/kg/
cm2 applied to a 6 cm2 versus an 18 cm2 application area was
determined. This threefold increase in application area resulted in
significantly enhanced decorporation and a significantly reduced
liver 241Amburden comparedwith the untreated control (p<0.001
and p<0.001, respectively) and 200 mg/kg dose treatment groups
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(p<0.001 and p<0.05, respectively) (Table II). The daily excretion
of 241Am in the urine (Fig. 3a) and feces (Fig. 3b) demonstrated
that elevated 241Am levels in the urine and feces were consistently
achievedwhen the gel was applied to an 18-cm2 area, compared to
untreated controls as well as to animals that was treatedwithC2E5
doses of 200 and 600 mg/kg applied over a 6-cm2 area.
DISCUSSION
Transdermal drug delivery possesses many advantages
over other drug delivery routes such as parenteral and oral
routes. These includes the delivery of a steady-state profile
that reduces side effects related to fluctuations in plasma drug
concentration, reduced dosing frequency, avoidance of first
pass metabolism, and improved patient compliance due to its
convenient and noninvasive means of self-administration
(19,20,25). It may also offer benefits to special populations
such as patients with needle phobia, those who are uncon-
scious or too nauseated to take oral medications, pediatric
patients, and the elderly. The latter two populations are
specific areas of concern to the FDA related to the
development of radionuclide decorporation agents (26). The
stringent physicochemical requirements for potential trans-
dermal drug candidates have limited the number of commer-
cial transdermal drug products on the market (19,20). The
DTPA prodrug, C2E5, was synthesized, determined to
possess suitable physicochemical properties for transdermal
delivery (21,22), and achieved sustained release of C2E5
metabolites when applied topically to rats in a nonaqueous
gel formulation (23).
In the present study, the elimination profile for C2E5 was
obtained, and dose- and area-dependent radionuclide
decorporation efficacy profiles following transdermal application
were demonstrated. The mass balance study using [14C]-labeled
C2E5 nonaqueous gels showed that approximately 62% of the
appliedC2E5 dosewas absorbed in 24 h and that about half of the
absorbed dose was eliminated in the urine. The overall [14C]
recovery for the study was 93%, a satisfactory end point for a
mass balance study using rats, where at least 90% recovery is
defined as acceptable (27). The small amount of [14C] recovered
from the skin application site indicated that C2E5 did not reside
there for an extended period after administration, thus avoiding
potential skin irritation and inflammation issues associated with
drug retention at the application site. The fact that no signs of
irritation were evident on visual inspection of the application site
further confirmed the suitability of C2E5 for transdermal
delivery. The daily excretion of [14C] radioactivity in urine and
feces (Fig. 2) showed sustained excretion of C2E5 and
metabolites over 72 h following the removal of C2E5 gels from
the application site. In addition, the recovery of most of the
absorbed radioactivity in the excreta and the low residual
radioactivity in the liver suggests that C2E5 and its metabolites
were not retained in tissues.
We observed that about half of the absorbed C2E5 dose
was eliminated in the urine over 6 days after topical
administration. In contrast, i.v. DTPA results in ≥90% renal
clearance within 24 h of administration (12,13). C2E5 is
metabolized by esterases in the skin and plasma in a stepwise
manner, yielding metabolites such as DTPA, C2E1, and C2E2
(23); compounds that are more lipophilic than DTPA are known
to shift elimination of actinides from a predominantly renal
pattern to a pattern with increased fecal excretion (28,29). It is
anticipated that these partially hydrolyzed C2E5 metabolites
(C2E2 and C2E1) can form relatively stable chelating complexes
with transuranic elements, such as 241Am, with log stability
constants in the range from 16.3 to 24.0M−1 (30,31). Even though
such complexes are less stable than the 241Am-DTPA complex,
theymay result in increased 241Am decorporation consistent with
the results observed in the C2E5 gel decorporation study. A
strong temporal relationship was observed when the daily
excretion of [14C] in the urine is compared with the urinary
Fig. 1. Structures of C2E5 and its metabolites. For the study using radiolabeled C2E5, the C-14 label was on the carbonyl
carbons of C2E5 and is retained on all C2E5 metabolites
Table I. Percent of Administered Dose in Various Tissues 6 Days
After Administration of [14C]-Labeled C2E5 Nonaqueous Gels at a




Skin at the application site 1.57 0.28
Liver 0.11 0.30
Recovered gel from the application site 30.8 6.6
Mass balance 93.0 3.9
*Include [14 C] recovered from cage washes
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fraction of the 241Am decorporation. The relationship between
fecal 241Am decorporation and the content of [14C] in the feces
was less clear, possibly due to delayed biliary excretion of the
chelation complex and intestinal transit time. These observations
are consistent with earlier reports, where delayed excretion of
transuranic radionuclides, such as 238Pu, 239Pu, and 241Am, after
chelation with DTPA or other decorporation agents was
observed in dogs and rodents (17,28,32).
Animal models have been developed to facilitate the
understanding of the biokinetic profiles that are observed following
contamination by transuranic elements (14). For the model used in
this study, a simulated wound contamination with [241Am]-
americium nitrate, the 241Am at the intramuscular contamination
site initially enters the bloodstream as the stable trivalent 241Am3+
form.Once in the circulation, approximately 95%of the 241Am3+ is
cleared or redistributed from the plasma in less than 1 h, with the
majority accumulating in the liver and skeleton (33–35). An
adequate concentration of a chelator in the blood can sequester
the 241Am3+ as a stable chelation complex, reducing the
translocation and deposition of radionuclides into the adjacent
bone, liver, and other tissues. In addition to promote the excretion
of 241Am3+, Markley reported that intraperitoneally administered
DTPA penta-ethyl ester successfully reduced the 239Pu content in
mouse liver (36). Guilmette et al. demonstrated that i.v.
administration of a series of mono- and dialkyl esters of DTPA
(including a form of C2E1 and C2E2, respectively) effectively
reduced the plutonium burden in the skeleton of contaminated
rodents (37). Because the biokinetics of 242Cm and 244Cm are very
similar to that for 241Am (35), the effective decorporation
treatment for 241Am would also likely be effective in treating
individuals contaminated with 242Cm and 244Cm. Thus, the
previous reports suggest that this C2E5 gel treatment may
promote the excretion of several transuranic elements in addition
to 241Am.
In the studies reported here, a well-defined C2E5 dose-
dependent increase in excretion of 241Am in the urine and feces
was observed for animals treated with the C2E5 gels 24 h post
contamination; total body decorporation of 241Am increased by
approximately 2% for every 100 mg/kg of administered C2E5. A
similar trend was observed for the reduction in the liver 241Am
burden; each 100 mg/kg increment of C2E5 dose reduced the liver
241Am burden by approximately 1%. Although the reduction in
skeleton burden for 24 h post contamination C2E5 gel groups did
not appear to be dose dependent, a lower skeletal burden was
observed in contaminated animals treated with C2E5 gels at all
dose levels compared to untreated animals. As the liver and bone
tissues are key target organs for the chronic damage caused by
radionuclide contamination (38,39), this improved ability for C2E5
metabolites to remove actinides fixed in liver and bone tissues may
result in a therapeutic benefit. In addition to demonstrating a dose-
dependent response to C2E5 treatment when applied to the same
area, we also demonstrated increased efficacy when the application
area was increased from 6 to 18 cm2. Based on Fick's law, the drug
flux across the skin is directly proportional to the drug application
area when all other parameters are kept constant. For animals




















Days Post [14C]C2E5 Gel Application
Fig. 2. Daily excretion of radioactivity in urine and feces after topical application of [14C]-
labeled 40% C2E5 nonaqueous gels (data are means ± S.D.) (n=6). (urinary excretion, ;
fecal excretion, )
Table II. 241Am Recovered in Samples 7 Days Following Single-Dose Treatments 24 h Post i.m. Contamination of Rats with 241Am Nitrate (%
of ID of 241Am)
Treatment Application area
Total excretion
(urine + feces) Liver Skeleton Wound site Total recovery
Untreated control (n=4) N/A 13.7±2.6 23.6±1.4 16.3±1.3 30.2±4.9 86.3±3.4
i.v. Ca-DTPA 14 mg/kg (n=8) N/A 37.7±4.0*** 12.1±1.6*** 11.7±2.2* 24.7±6.1 88.6±2.1
C2E5 gel 200 mg/kg (n=7) 6 cm2 18.8±3.1### 19.2±2.4*### 14.0±3.1 31.7±7.5 87.9±2.1
C2E5 gel 600 mg/kg (n=8) 6 cm2 24.5±3.2***### 16.2±3.1***## 13.5±1.8 30.4±5.3 87.5±1.7
C2E5 gel 1,000 mg/kg (n=8) 6 cm2 33.3±3.7*** 13.1±1.3*** 12.5±2.0* 23.0±6.1 86.8±2.1
C2E5 gel 600 mg/kg (n=4) 18 cm2 32.7±5.6*** 14.6±2.1*** 12.9±1.3 24.9±7.5 88.5±1.3
Significant difference by one-way ANOVAwith Tukey's post hoc comparison of means, *p<0.05, **p<0.01, and ***p<0.001 against untreated
control; # p<0.05, ## p<0.01, and ### p<0.001 against i.v. Ca–DTPA treatment. N/A not applicable
1185Transdermally Delivered Prodrug for Decorporation
6 cm2 or at 600 mg/kg dose applied over 18 cm2, the
overall efficacy in terms of enhancement in decorporation
as well as reduction in liver and skeletal burden was comparable
to that observed for animals intravenously administered Ca–
DTPA at the standard recommended dose of 14 mg/kg.
All animals were examined daily during the experimental
period for indications of disease or abnormalities including
morbidity, mortality, and signs of toxicity (no radiotoxicity was
anticipated due to the low amounts of 241Am employed in these
studies). In C2E5 treated animals, no elevated skin reddening or
local skin inflammation was observed at the locus where the dose
was applied, and gel treatment did not significantly alter animal
body weights compared with untreated control animals. These
preliminary results suggest that the C2E5 gel was well tolerated
by the animals. The 241Am content at the wound site for all the
experimental groups was consistent with literature reports (14),
and no statistical significance was observed in the retained 241Am
at wound sites among the different treatment groups. The
radionuclide decorporation results confirmed the validity of
maintaining chelator concentrations for an adequate duration to
ensure optimal in vivo chelation of transuranic radionuclides (15).
Unlike most new drug candidates, the efficacy of radionu-
clide decorporation therapies has not been systemically evaluated
in human clinical trials due to ethical concerns involving the
contamination of healthy human subjects with radionuclides. The
“animal rule” (21 CFR 314.600) has been implemented by the
FDA as a paradigm for the approval of drugs that treat
radiological, chemical, and biological threats (40,41). The 241Am
decorporation results in the rodent wound contamination model
presented here demonstrate that this treatment option can be as
effective as the current FDA-approved i.v. DTPA treatment
when administered 1 day after radionuclide contamination, a
realistic response timeframe for victims in a mass casualty
scenario after a nuclear/radiological event that has been
adopted within the concept of operations by both the National
Institute of Allergy and Infectious Diseases and the Biomedical
Advanced Research and Development Authority.
In order to predict an appropriate human dosing regimen for
this transdermal gel treatment based on rodent efficacy data,
interspecies differences in the drug's pharmacokinetics need to be
considered. Based on allometric scaling (42), the 6 cm2 application
area used on the ∼250 g rats would translate to a gel application
area of approximately 300 cm2 (a circlewith a radius of∼10 cm) for
a 70 kg human; this application area is within the range of current
topical products (43). The renal clearance of chelators likeDTPA is






























































Fig. 3. Daily excretion of 241Am in urine (a) or in feces (b) after a single dose of the
decorporation agents at different dose levels and application areas 24 h post
contamination. Significant (*p<0.05, **p<0.01, and ***p<0.001) by Dunnett's test.
(Untreated control, ; 200 mg/kg applied to 6 cm2, ; 600 mg/kg applied to 6 cm2,
; 1,000 mg/kg to 6 cm2, ; and 600 mg/kg to 18 cm2, )
1186 Zhang et al.
(44), which, for a given dose, would result in a higher steady-state
plasma concentration in humans. It has also been demonstrated
that the DTPA plasma concentration required to quantitatively
bind 241Am in rat plasma is approximately threefold greater than
in human plasma (45). These two factors may result in a lower
dose being required for human efficacy. The dose may be further
lowered by increasing the frequency of dosing.
CONCLUSIONS
To our knowledge, this is the first report which demonstrates
that the transdermal delivery of a pro-chelator is a viable strategy
for delivering chelating agents to the systemic circulation, resulting
in an effective, mass-casualty-ready treatment option for radionu-
clide contamination. Efficacy was demonstrated by enhancing total
body decorporation and reducing the liver and skeletal burden of
241Am with a single topical administration of the C2E5 gel 24 h
after contamination. Enhanced 241Am elimination for at least
3 days after application indicated that the C2E5 nonaqueous gels
provided sustained delivery of metabolites capable of chelating
241Am. No skin abnormalities or signs of skin irritation were
observed after administration of the C2E5 nonaqueous gel
throughout the entire study period. The effectiveness of this
treatment option, favorable sustained release profile of pro-
chelators, and ease of administration support the use of C2E5
nonaqueous gels following nuclear/radiological emergencies and
for its inclusion in the Strategic National Stockpile.
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